戻る
Bioatla Inc (BCAB)価格
BCAB 株価推移チャート
BCAB 財務
Bioatla Inc
$0.32
0.81%
$0
終値： Jan 16, 16:00:00 GMT-5
$0.31
-1.55%
$0
アフターマーケット：Jan 16, 20:00:00 GMT-5
主要データ
前終値
$0.3196
始値
$0.32
当日レンジ
$0.3172 - $0.3654
52週レンジ
$0.24 - $1.43
取引高
1.7M
平均取引高
1.8M
1株当たり利益(TTM)
-0.57
配当利回り
--
時価総額
$18.6M
BCABとは何ですか？
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.